Compare Domino's Pizza, Inc. (DPZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Pfizer Inc — how do they compare? Domino's Pizza, Inc. trades at $308.02 (market cap $10.03B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 15.9× Domino's Pizza, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Pfizer Inc for 158 Days on average.
| DPZ | PFE | |
|---|---|---|
Market Cap | $10.03B | $159.59B |
Volume | 892,489 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $29.02 |
52-Week Low | $282.89 | $23.67 |
Typical Hold Time | 106 Days | 158 Days |
Enterprise Value | $14.99B | $211.09B |
Dividend Yield | 2.63% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $308.65, up 1.91% today, with a bullish technical signal despite recent earnings misses. Revenue has grown steadily to $4.94B in 2025, with a net margin of 11.86%, though the stock faces headwinds from high debt levels and flat dividend growth. Analyst consensus is a Buy with a $373 price target, but news highlights store closures and competitive pressures.
The outlook is mixed: strong cash flow and brand strength support upside, but debt burden and margin pressure pose risks. Investors should weigh analyst optimism against execution challenges in a competitive sector.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
